339 related articles for article (PubMed ID: 31884070)
1. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
[TBL] [Abstract][Full Text] [Related]
2. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR for cancer therapy.
Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
6. Current treatment strategies for inhibiting mTOR in cancer.
Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.
Nagini S; Sophia J; Mishra R
Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927
[TBL] [Abstract][Full Text] [Related]
8. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
9. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
11. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
Tian T; Li X; Zhang J
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754640
[TBL] [Abstract][Full Text] [Related]
12. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
13. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
14. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
17. Revisiting mTOR inhibitors as anticancer agents.
Teng QX; Ashar YV; Gupta P; Gadee E; Fan YF; Reznik SE; Wurpel JND; Chen ZS
Drug Discov Today; 2019 Oct; 24(10):2086-2095. PubMed ID: 31173912
[TBL] [Abstract][Full Text] [Related]
18. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
19. mTOR in Lung Neoplasms.
Krencz I; Sebestyen A; Khoor A
Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
[TBL] [Abstract][Full Text] [Related]
20. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
